Why men age faster but reproduce longer than women:  mTOR and
































Longevity: men and women 
 
  Women have lived longer than men in different 
countries and in every era [1]. In 1980 in the USA, the 
estimated life expectancy at birth was 70 years for men 
and 77.5 years for women [2]. In the world, 75% and 
90% of people older than 100 years and 110 years 
(respectively) are women. And the longest living person 
(122 years old) was a woman. But do women age slower 
than men? The conventional opinion is that women and 
men age at the same rate but men are ‘less robust’ than 
women [1]. Seemingly in agreement, the mortality rate is 
lower in young women compared with young men. In 
women, the mortality rate is lower at every age, even in 
childhood. In other words, “women do not live longer 
than men because they age slowly, but because they are 
more robust at every age” [1]. This reasoning would be 
correct if causes of death were the same at every age. 
However, young and old men die from different causes. 
Young men die from accidents, while old men die from 


































High accidental death rate and fast aging 
(evolutionary perspective) 
 
There is a very noticeable jump of mortality in the late 
teens in men [1]. Young men are often engaged in 
competitive, reckless, and dangerous activities. 
Therefore, even in modern society, the accidental 
death rate is high in young men. Historically, the 
accidental death rate in men was much higher than it is 
now. (Due to a fierce competition for status and mates, 
due to fights and wars, young men were killed at a 
very high rate). So, historically, men had lower 
chances to survive into old age than women had. And, 
according to evolutionary theory, a high accidental 
death rate determines fast aging [3-5]. If most men 
died young from accidental death, then they could not 
live long enough to experience aging. Then there was 
no natural selection to postpone aging. So accelerated 
aging in men is predictable from evolutionary 
perspective. But accelerated aging is also predictable 
mechanistically.  
 























quasi‐program  causes  over‐activation  of  female  reproductive  system,  which  is  very  vulnerable  to  over‐activation.
Mechanisms of aging and menopause are discussed. 
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and mTOR  
 
In males, muscle hypertrophy and heavy body helps to 
compete with other males. (In fact, men are larger than 
women.)  Cellular growth and hypertrophy are stimulat-
ed by the mTOR (mammalian Target of Rapamycin) 
intracellular signaling pathway. Insulin, growth factors, 
amino acids, glucose lipoproteins, and testosterone all 
activate the mTOR pathway [6-9].   In turn, the mTOR 
pathway stimulates protein synthesis and cell size 
growth [10]. For example, skeletal muscle hypertrophy 
depends on the mTOR pathway [11, 12]. In addition, 
inhibition of the mTOR pathway decreases testosterone 
levels and spermatogenesis [13]. Thus, activation of 
mTOR may provide a selective advantage to young 
males.   
 
On the other hand, the mTOR pathway is required 
forcellular senescence of mammalian cells [14-18]. 
Cellular aging is driven by the remaining activation of 
mitogenic signaling pathways in post-mitotic cells [19, 
20]. In fact, mechanistically, aging is a continuation of 
growth, driven in part by mTOR [21].  In agreement, 
mTOR is involved in age-related diseases such as 
atherosclerosis, neurodegeneration, cancer, which are 





























And rapamycin prolongs lifespan in mammals [25]. 
 
Thus, over-activation of mTOR may provide an 
advantage (muscle hypertrophy, high levels of 
testosterone and high spermatogenesis) in early life at 
the cost of accelerated aging later in life. As an 
illuminating example, mice over-expressing growth 
hormone exhibit increased levels of IGF-I and adult 
body size, reduced life span and reproductive life span 
[26]. (Note: IGF-I stimulates mTOR, Figure 1). 
 
Accelerated age-related diseases in men  
 
Humans do not die from “healthy” aging. Humans die 
from age-related diseases. The mTOR pathway is 
involved in age-related diseases such as cancer, 
atherosclerosis, hypertension, heart failure, osteo-
porosis, type II diabetes [22, 24, 27]. These diseases are 
deadly manifestations of aging. When aging is 
accelerated, age-related diseases occur earlier in life too. 
Healthy aging (a late onset of diseases) is associated 
with longevity (see for discussion [28]). For example, 
centenarians (100 years old or older) show a delay in 
the onset of age-related diseases, including cardio-
vascular disease, type 2 diabetes, cancer and 
Alzheimer’s disease. In other words, those who age 
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diseases must be delayed in women. In fact, most age-
related diseases are delayed in women compared with 
men. For example, coronary atherosclerosis is 
postponed in women. Not only atherosclerosis, but also 
cancer and most other diseases of aging occur earlier in 
men than in women [31]. Women also live more years 
than men free of each of these diseases with the 
exception of arthritis [32]. Women rarely die from age-
related diseases before menopause. The later onset of 
diseases in women compared with men suggests that 
women age slower than men.  
 
Intriguingly, slower erosion of human telomeres favor 
females [33] and, even further, the rate of leukocyte 
telomere shortening predicts mortality from cardio-
vascular disease in elderly men [34]. I speculate that 
high rate of telomere shortening reflects cellular hyper-
activation and may be suppressed by rapamycin. 
 
Aging versus reproductive aging  
 
Yet common wisdom holds that women age faster than 
men. One should not confuse aging and subjective 
perception of youthfulness and sexual attractiveness, 
which reflects fertility. Aging is an increase of the 
probability of death. And a 50-year-old man has higher 
chances to die than a 50- year-old woman. Furthermore, 
men acquire grey hair and wrinkles faster than women 
and thus men even ‘look’ older [35]. Although men age 
faster, they can reproduce longer. And here is another 
puzzle: why women undergo menopause.  
 
Like aging itself, menopause is tolerated by natural 
selection, because women (until recently) did not live 
long enough to experience it. (In modern society, there 
must be a very strong natural selection for delayed 
menopause). So an evolutionary explanation is simple: 
ancestral women did not live long enough to have 
menopause. But male lifespan was even shorter: why 
then do men not have menopause? What is so special 
about female reproduction?   
 
Can menopause be programmed? 
 
There is common opinion among traditional 
gerontologists that menopause is beneficial for women, 
has an evolutionary advantage and is adaptive [36-38]. 
It was suggested, for instance, that menopause prevents 
death of women in labor. The most popular is a 
“grandmother hypothesis” that menopause frees older 
women to help their daughters to raise grandchildren. 
This is a sort of group-selection hypothesis. Why do not 
daughters delay reproduction just in order to help their 
mothers raise siblings?  Or what is the biological sense 
to stop reproduction, if a woman has no grandchildren 
living with her? The crucial assumption of 
‘grandmother’ hypothesis is that menopause occurs only 
in humans [37]. Yet, menopause was documented in 
non-human primates, rodents, whales, dogs, rabbits, 
elephants and domestic livestock [39]. It was shown, for 
instance, that mice eventually undergo ovarian changes 
analogous to menopause in humans [40, 41]. 
 
 It was shown that grandmothers may promote survival 
of their maternal grandchildren in Gambia [37]. 
Grandmothers are useful but menopause is not. There is 
no experimental evidence that menopause is beneficial 
even when women live with grandchildren in Gambia. 
Menopause accelerates age-related diseases such as 
atherosclerosis, osteoporosis and cancer [42, 43]. 
Reproductive death provides no selective benefit (unless 
group-selection theories of aging are correct) and 
‘grandmother hypothesis’ contradicts the evolutionary 
theory. If aging is not programmed, then reproductive 



























TOR-driven quasi-programmed aging  
 
Aging is not programmed but quasi-programmed [22, 
44-46]. (“Quasi-” means  “as if, resembling”). Quasi-
program is an aimless continuation of a useful program 
that was not switched off upon its completion. Unlike a 
program, a quasi-program has no purpose. Develop-
mental programs become aimless quasi-programs later 
in life. Quasi-programs are driven by antagonistic 
pleiotropic genes, which are beneficial early in life on 
the cost of aging later in life. Most genes that control 
aging and longevity constitute the mTOR pathway [22, 
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development [47, 48]. In post-development, mTOR is 
involved in aging and age-related diseases [22].  
 
Nutrients activate mTOR and cause insulin-resistance in 
cell culture [49, 50] as well as systemically in rodents 
and humans [51-54]. There is a negative feedback loop 
between insulin signaling and TOR (Figure 2). When 
mTOR is activated, it blocks insulin signaling (insulin 
resistance) [49, 55]. Noteworthy, insulin resistance is 
associated with premature menopause in some patients 
[56].  
  
The menstrual cycle is fragile 
 
Since aging is not programmed, it does not hurt on 
purpose. It does not cause ovarian failure (menopause) on 
purpose. The logic of aging is simple: the most fragile 
systems fail first. A female reproductive system is 



































The hypothalamus and ovaries, communicating via 
dozens of hormones. The menstrual cycle is regulated 
by interplay of negative and positive feedback loops. 
The hypothalamus stimulates the pituitary gland to 
secrete Follicle-Stimulating Hormone (FSH), which in 
turn stimulates follicles in the ovaries (Figure 3). 
Follicles maturate and secrete estrogens. Estrogens 
inhibit the hypothalamus, decreasing secretion of FSH 
(a negative feedback loop).  In turn, FSH stimulates 
ovarian follicles, which produce estrogens, which in 
turn inhibit FSH production. Also, estrogens stimulate 
secretion of Lutenizing Hormone (LH). LH in turn 
causes ovulation. So for the normal menstrual cycle, the 
hypothalamus should have a narrow range of sensitivity 
to estrogens. Both too high and too low sensitivities are 
not compatible with menstrual cycles. In comparison, 
regulation of reproduction in men is simpler. There is a 
gradual decrease in fertility in men too (analogous to 
pre-menopause), although this usually does not result in 






































inhibit  FSH  production  (negative  feedback).  (A)  In  girls,  the  hypothalamus  is  extremely  sensitive  to
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A half century ago, Vladimir Dilman proposed a 
“biological clock” that initially launches reproduction in 
puberty and then causes menopause [59, 60]. This idea 
is absolutely compatible with quasi-programmed nature 
of menopause, as discussed herein. 
 
Before puberty, the hypothalamus is extremely sensitive 
to estrogens (Figure 3 A). Even low levels of estrogens 
suppress FSH production and, therefore, levels of FSH 
are low. At puberty, the hypothalamus becomes more 
resistant to estrogens. Then low levels of estrogens 
cannot suppress FSH. FSH in turn stimulates the 
ovarian follicles. Follicles produce estrogens, which in 
turn inhibit FSH production (Figure 3 B). During 
lifetime, resistance to estrogens continues to increase 
(Figure 3C). This ever-increasing resistance is an aim-
less continuation of the same program that initiated 
menstrual cycle at puberty.  FSH is elevated in pre-
menopause and rising serum FSH levels is one of the 
earliest signs of human female reproductive aging [61], 
[62]. Rising FSH levels over-stimulate the ovaries 
(Figure 3C), thus depleting follicles (Figure 3D).  
 
FSH hyper-stimulates the ovaries, causing more 
follicles to be recruited simultaneously (Figure 3 C). 
This may explain the increased tendency of older 
mothers to have dizygotic twins [63]. Due to 
hypothalamic resistance to estrogens, estrogens cannot 
induce LH surges, which are necessary for ovulation. 
Therefore, follicles are recruited without progression to 
ovulation. Therefore, fertility gradually decreases long 
before menopause.   
 
Hypothalamic resistance to estrogens causes higher 
FSH levels and lower LH pulses, disturbed feedback 
relationships and decrease in fertility [64]. Levels of 
estrogens tend to be increased in pre-menopause [64], 
but even increased estrogens cannot suppress FSH [61]. 
FSH over-stimulates follicle recruitment, leading 
eventually to follicular depletion (Figure 3D). This 
process eventually results in ovarian failure (Figure 3 
D). Post-menopause is characterized by a drop in 
estrogen levels because of the depletion of follicular 
oocytes that normally produce estrogen (Figure 3 D).  
 
Noteworthy, aged mouse ovaries possess rare 
premeiotic germ cells that can generate oocytes 
following transplantation into a young host environment 
[65], and even further young adult donor bone marrow 
infusions into female mice postpone age-related 
reproductive failure [66]. In other words, some follicles 
may become unresponsive due to age-associated over-
stimulation but can be rejuvenated. 
Thus, reproductive aging is set in motion at puberty by 
an ever-increasing hypothalamic resistance to estrogens.  
By increasing resistance of the hypothalamus to 
estrogens, the developmental program establishes the 
menstrual cycle at puberty. There is no program to 
cause menopause. It simply happens because resistance 
to estrogens (and some other hormones) is ever-
increasing. This is an example of a quasi-program, a 
continuation of a program that was not switched off 
upon its completion (at puberty). The quasi-program 
interrupts the same reproductive function that the 
program establishes. The same mechanism (resistance 
of the hypothalamus to estrogen) first starts and then 
ends reproduction in women. An increased resistance to 
estrogens can explain both initiation and termination of 
the menstrual cycle.  
 
How may we explain an increased resistance to 
estrogens? Resistance may be secondary to hyper-
stimulation by estrogens themselves. In fact, in old 
acyclic mice, ovariectomy for 2 months partially reversed 
the hypothalamic resistance [41]. Hyper-stimulation of 
the hypothalamus by estrogens may cause resistance, in 
turn increasing stimulation of the ovary, until failure 
occurs. Alternatively, overstimulation of the 
hypothalamus with hormones and nutrients can cause 
estrogen-resistance. Is there a feedback resistance to 
overstimulation as shown in Figure 2? Then over-
stimulation, with secondary resistance, is the driving 
cause of reproductive program and quasi-program. And 
most importantly over-stimulation occurs simultaneously 
both in the ovary and the brain. 
 
mTOR and menopause 
 
I propose that the increasing activation of mTOR (both 
in the hypothalamus and the ovary) drives hormone 
resistance, causing the onset of reproduction and then 
hyper-stimulation of the ovary and the hypothalamus 
and finally menopause (Figure 4).  Let us bring together 
several pieces of data. 
 
First, mTOR is a regulator of puberty onset via 
modulation of the hypothalamus [67]. Also, both FSH 
and estrogens activate the mTOR pathway [68], [69]. So 
if TOR is activated constantly, it may not respond 
further to stimulation (hormone resistance).  
 
Second, in mice lacking PTEN  in oocytes, the entire 
primordial follicle pool is activated. Subsequently, all 
primordial follicles become depleted in early adulthood, 
causing premature ovarian failure [70]. PTEN loss 
results in suppression of Foxo, so the Foxo was a primer 
suspect [70]. Yet, in theory loss of PTEN must also 
result in mTOR overactivation (Figure 1). I suggest that  
   





















premature ovarian failure is caused by over-activation 
of TOR. (Note: this paper was initially written in 2008 
and was ahead of its time and was not well received by 
conventional journals. Now it can be updated). It was 
shown tuberous sclerosis complex (Tsc), which 
negatively regulates mTOR, functions in oocytes to 
maintain the quiescence of primordial follicles. In 
mutant mice lacking the Tsc1 gene in oocytes, the entire 
pool of primordial follicles is activated prematurely due 
to elevated mTORC1 activity in the oocyte, ending up 
with follicular depletion in early adulthood and causing 
premature ovarian failure [71, 72]. 
 
Third, calorie restriction (CR) prevents age-related 
increase in estrogen resistance in the hypothalamus of 
old female mice [73]. As already discussed, CR de-
activates TOR [74]. I speculate that CR de-activates 
mTOR and delays estrogen resistance in the 
hypothalamus. Simultaneously, by deactivating mTOR 
in the oocytes, it may delay their depletion. 
 
It was shown almost a century ago [75] and then 
reproduced numerous times that CR extends lifespan 
and prevents age-related infertility in rodents. In most 
of these studies, CR was initiated at weaning, causing a 
delayed onset of sexual maturation. So, the same 
condition (CR) delays both puberty and menopause. 
This is consistent with the notion that a quasi-program 
(menopause) is a mere continuation of the program 
(puberty).  But quasi-programs can be manipulated, 
exactly like programs.  Recently it has been shown that 
a moderate caloric restriction initiated in rodents during 
adulthood sustains reproductive function of the female 



























Fifth, metformin, an antidiabetic drug, activates AMPK 
and thus inhibits mTOR [77]. Furthermore, metformin 
inhibits mTOR in AMPK-independent manner too. 
Metformin restores ovulations in patients with 
premature menopause associated with polycystic ovary 
syndrome [56]. On the other hand, metformin delays a 
premature onset of the menstrual cycle [78]. So the 
same agent that inhibits the onset of reproductive 
function also inhibits its termination. This antagonistic 
pleiotropic effect is consistent with the notion of the 
same mechanism switching reproduction on and off. 
Metformin slowed down aging and the age-related 
switch-off of estrous function in mice [79]. Thus 




This article presents two hypotheses. The first 
hypothesis explains (from both an evolutionary and 
mechanistic perspective) why aging is accelerated in 
men.  From the evolutionary perspective, the high 
accidental death rate in young men determines an 
accelerated aging. A model of TOR-driven aging 
provides a mechanistic explanation. When the 
accidental death rate is high, it is important to be bigger 
and stronger.  And the mTOR pathway is involved in 
growth and cellular hypertrophy. So, overactivated 
mTOR may be adaptive for young men.  
 
But this can accelerate aging. At the cost of accelerated 
aging, over-stimulated mTOR pathway may provide an 
advantage earlier in life. And vice versa as discussed, 
“weak mTOR”  provides disadvantage earlier in life 
and, vice versa, robustness and fast aging are associated 
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among men is associated with atherosclerosis and 
earlier death from age-related coronary disease [80]. 
 
The second hypothesis explains why menopause in 
women occurs despite slow-aging. Simply, the 
regulation of the menstrual cycle is fragile. There is a 
fine balance between ovarian stimulation by FSH and 
feedback hypothalamic responsiveness to estrogens. 
The menstrual cycle is vulnerable. Menopause is an 
example of a quasi-program (a program that was not 
switched off after its completion). In puberty, an 
increasing resistance to estrogen starts reproduction (a 
program). A further increase in the resistance (a quasi-
program) causes overactivation of the ovary, decreasing 
fertility. This process can be treated pharmacologically 
(as any other age-related disease) to postpone menopause 
Potential therapeutic interventions to postpone 
menopause (as well as abolishment of the harmful 
consequences of menopause) will be discussed in 
forthcoming book The Origin of Aging. 
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